Drug Trial Radar · NCT06058039
Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder
Last checked: Nov 20, 2026Latest source record: Jul 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
422
Actual
Start
Dec 21, 2023
Primary completion
May 4, 2026
Study completion Jun 11, 2026
Sponsor
- Lead sponsor
- Neumora Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 28, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized, double-blind, placebo-controlled, multicenter study will evaluate the effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 35 days), and a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and meet the eligibility criteria may enter an open-label extension study (NMRA-335140-501).
Conditions
- Major Depressive Disorder
Interventions
NMRA-335140Drug
Participants will receive NMRA-335140 at a dose of 80 mg QD, orally
PlaceboDrug
Placebo will be administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline to Week 6 in the Montgomery-Asberg Depression Rating Scale (MADRS) total scoreTime frame: Baseline and up to Week 6
Locations
71 sites in 8 countries. Site status is shown where the registry gives one.
Neumora Investigator Site
Cerritos, California
Neumora Investigator Site
Irvine, California
Neumora Investigator Site
Long Beach, California
Neumora Investigator Site
San Diego, California
Neumora Investigator Site
San Francisco, California
Neumora Investigator Site
New Haven, Connecticut
Neumora Investigator Site
Brandon, Florida
Neumora Investigator Site
Hialeah, Florida
Neumora Investigator Site
Hialeah, Florida
Neumora Investigator Site
Jacksonville, Florida
Neumora Investigator Site
Miami, Florida
Neumora Investigator Site
Miami, Florida
Neumora Investigator site
Miami, Florida
Neumora Investigator Site
Miami Beach, Florida
Neumora Investigator site
Miami Springs, Florida
Neumora Investigator Site
Palm Bay, Florida
Neumora Investigator Site
Pembroke Pines, Florida
Neumora Investigator Site
Pompano Beach, Florida
Neumora Investigator Site
Saint Augustine, Florida
Neumora Investigator Site
Atlanta, Georgia
Neumora Investigator Site
Decatur, Georgia
Neumora Investigator Site
Savannah, Georgia
Neumora Investigator Site
Springfield, Massachusetts
Neumora Investigator Site
St Louis, Missouri
Neumora Investigator Site
Omaha, Nebraska
Neumora Investigator Site
Berlin, New Jersey
Neumora Investigator Site
New York, New York
Neumora Investigator Site
New York, New York
Neumora Investigator Site
Staten Island, New York
Neumora Investigator Site
Charlotte, North Carolina
Neumora Investigator Site
Austin, Texas
Neumora Investigator Site
DeSoto, Texas
Neumora Investigator Site
Fort Worth, Texas
Neumora Investigator Site
Plano, Texas
Neumora Investigator Site
Kardzhali, Bulgaria
Neumora Investigator Site
Pleven, Bulgaria
Neumora Investigator Site
Targovishte, Bulgaria
Neumora Investigator Site #1
Varna, Bulgaria
Neumora Investigator Site
Varna, Bulgaria
Neumora Investigator Site
Cherven Bryag, Pleven, Bulgaria
Showing 40 of 71 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.